Product image of Metformina + Sitagliptina Yrik (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Yrik

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Yrik (Metformin Hydrochloride, Sitagliptin)

Metformin and Sitagliptin, the active ingredients in Metformina + Sitagliptina Yrik, are a Biguanide and a DPP‑4 inhibitor presented as a tablet for oral use. They are prescribed to improve blood‑glucose control in adults with type 2 diabetes mellitus.

GNH India supplies Metformina + Sitagliptina Yrik as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratórios Basi – Indústria Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina Yrik is used in the management of type 2 diabetes mellitus, acting on multiple glucose‑regulating pathways.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels and reduces HbA1c when added to diet and exercise.
  • Inadequate control on metformin alone: provides additional glycaemic reduction as part of combination therapy.
  • Adjunct to insulin therapy: helps achieve target glucose levels while allowing lower insulin doses.

How It Works

  • Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), prolonging the activity of incretin hormones GLP‑1 and GIP. The combined effect increases insulin secretion, decreases glucagon release, and improves overall glucose homeostasis.

Side Effects

Metformina + Sitagliptina Yrik may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type headache.
  • Hypoglycaemia (when used with sulfonylureas or insulin): dizziness, sweating.
  • Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: severe metabolic acidosis, muscle pain, rapid breathing.
  • Pancreatitis: upper abdominal pain radiating to the back, nausea, vomiting.
  • Severe allergic reaction: rash, swelling, difficulty breathing.
  • Hepatic failure: jaundice, dark urine, fatigue.
  • Acute kidney injury: reduced urine output, swelling.
  • Cardiovascular events: chest pain, palpitations.

Precautions & Warnings

Before initiating Metformina + Sitagliptina Yrik, clinicians should consider several safety aspects.

  • Renal function assessment: avoid or adjust dose in patients with impaired renal function.
  • Hepatic disease evaluation: use with caution in liver disease due to lactic acidosis risk.
  • Alcohol consumption: limit intake as it may increase lactic acidosis risk.
  • Pregnancy and lactation: safety not established; weigh benefits against potential risks.
  • Concomitant medications: monitor for hypoglycaemia when combined with insulin or sulfonylureas.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Metformina + Sitagliptina Yrik can interact with several drug classes. Awareness of major and moderate interactions helps minimise adverse outcomes.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis.
  • Phenformin or other biguanides: combined use increases risk of lactic acidosis.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin plasma levels.
  • Alcohol excess: synergistic effect on lactic acidosis risk.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas or insulin: heightened risk of hypoglycaemia; dose adjustment may be needed.
  • Diuretics (especially thiazides): may affect renal clearance of metformin.
  • ACE inhibitors or ARBs: monitor renal function and electrolytes.
  • Beta‑blockers: may mask hypoglycaemia symptoms.
  • Rifampin: may reduce sitagliptin exposure, decreasing efficacy.

Frequently Asked Questions

Metformina + Sitagliptina Yrik is prescribed to improve blood‑glucose control in adults with type 2 diabetes mellitus. It combines two mechanisms—reduced hepatic glucose production and enhanced incretin activity—to lower fasting and post‑prandial glucose levels.

Metformin, a biguanide, decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity, allowing cells to take up glucose more efficiently. This reduces overall blood‑sugar concentrations and contributes to lower HbA1c levels.

The specific dose and dosing schedule are determined by the prescribing clinician based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions exactly.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Enquiries can be submitted via the product page on gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with metformin alone, the addition of sitagliptin provides greater HbA1c reduction without the weight gain often seen with sulfonylureas. Unlike insulin, it is administered orally and carries a lower risk of severe hypoglycaemia when used alone.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include lactic acidosis, a rare but potentially fatal condition, and pancreatitis. Patients should be educated to seek immediate medical attention for symptoms such as severe abdominal pain, rapid breathing, or unexplained fatigue.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. Contraindications are confirmed by the prescribing clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT